The RANTES-mediated targeting led to significant radioiodide accumulation in subcutaneous HCC xenografts after the systemic injection of MSCs engineered to express NIS under control of the RANTES promoter (RANTES-NIS-MSC). Here, SLC5A5 is linked to hepatocellular carcinoma.